Education
About Us
Working with TipRanks
Follow Us
Arcturus Therapeutics (ARCT)
NASDAQ:ARCT
Total Valuation
Arcturus Therapeutics has a market cap or net worth of $350.12M. The enterprise value is $194.71M.
Market Cap$350.12M
Enterprise Value$194.71M
Share Statistics
Arcturus Therapeutics has 27,119,823 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding27,119,823
Owned by Insiders8.43%
Owned by Institutions0.47%
Financial Efficiency
Arcturus Therapeutics’s return on equity (ROE) is -0.34 and return on invested capital (ROIC) is -34.34%.
Return on Equity (ROE)-0.34
Return on Assets (ROA)-0.24
Return on Invested Capital (ROIC)-34.34%
Return on Capital Employed (ROCE)-0.34
Revenue Per Employee875.34K
Profits Per Employee-465.18K
Employee Count174
Asset Turnover0.44
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Arcturus Therapeutics is -5.66. Arcturus Therapeutics’s PEG ratio is -0.03.
PE Ratio-5.66
PS Ratio2.29
PB Ratio1.90
Price to Fair Value1.90
Price to FCF-7.59
Price to Operating Cash Flow-7.67
PEG Ratio-0.03
Income Statement
In the last 12 months, Arcturus Therapeutics had revenue of 152.31M and earned -80.94M in profits. Earnings per share was -3.00.
Revenue152.31M
Gross Profit152.31M
Operating Income-95.67M
Pretax Income-80.94M
Net Income-80.94M
EBITDA-77.40M
Earnings Per Share (EPS)-3.00
Cash Flow
In the last 12 months, operating cash flow was -59.75M and capital expenditures 0.00, giving a free cash flow of -59.75M billion.
Operating Cash Flow-59.75M
Free Cash Flow-59.75M
Free Cash Flow per Share-2.20
Dividends & Yields
Arcturus Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.39
52-Week Price Change-51.52%
50-Day Moving Average13.23
200-Day Moving Average17.91
Relative Strength Index (RSI)60.04
Average Volume (3m)427.77K
Important Dates
Arcturus Therapeutics upcoming earnings date is May 12, 2025, TBA Not Confirmed.
Last Earnings DateMar 6, 2025
Next Earnings DateMay 12, 2025
Ex-Dividend Date―
Financial Position
Arcturus Therapeutics as a current ratio of 4.67, with Debt / Equity ratio of 11.85%
Current Ratio4.67
Quick Ratio4.67
Debt to Market Cap0.05
Net Debt to EBITDA2.74
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Arcturus Therapeutics has paid -4.00K in taxes.
Income Tax-4.00K
Effective Tax Rate<0.01
Enterprise Valuation
Arcturus Therapeutics EV to EBITDA ratio is -3.18, with an EV/FCF ratio of -4.08.
EV to Sales1.62
EV to EBITDA-3.18
EV to Free Cash Flow-4.08
EV to Operating Cash Flow-4.12
Balance Sheet
Arcturus Therapeutics has $237.03M in cash and marketable securities with $0.00 in debt, giving a net cash position of -$208.48M billion.
Cash & Marketable Securities$237.03M
Total Debt$0.00
Net Cash-$208.48M
Net Cash Per Share-$7.69
Tangible Book Value Per Share$8.93
Margins
Gross margin is 105.33%, with operating margin of -62.81%, and net profit margin of -53.14%.
Gross Margin105.33%
Operating Margin-62.81%
Pretax Margin-53.14%
Net Profit Margin-53.14%
EBITDA Margin-50.82%
EBIT Margin-53.14%
Analyst Forecast
The average price target for Arcturus Therapeutics is $66.00, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$66.00
Price Target Upside411.23% Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast-13.98%
EPS Growth Forecast-200.43%